longevity

DeSci making an appearance on The Genetics podcast is a big step. 

In genetics research and applications incentives are very much aligned towards cancer treatment. Bluntly, it’s because that is what pays (from insurance). Take any course or literature, the eventual end point is cancer treatment. And those incentives are not likely to change. Ask any Cardiologist trying to order genetic studies to check Plavix effectiveness.

DeSci seems the only way currently that personalized medical research and rare genetic diseases see light of day.

DeSci making an appearance on The Genetics podcast is a big step. 

In genetics research and applications incentives are very much aligned towards cancer treatment. Bluntly, it’s because that is what pays (from insurance). Take any course or literature, the eventual end point is cancer treatment. And those incentives are not likely to change. Ask any Cardiologist trying to order genetic studies to check Plavix effectiveness.

DeSci seems the only way currently that personalized medical research and rare genetic diseases see light of day.

https://podcasts.apple.com/us/podcast/the-genetics-podcast/id1462418412?i=1000691847568

Physician always trying to learn, passionate about healthspan and precision medicine.

omarsaleem.xyz

Has there been increasing funds towards longevity research in the past few years?

My assumption is that longevity is accelerating as a narrative but I have no idea if it's shifting big pharmas bottom line

Funding has definitely increased, but its come more from tech and VC rather than pharma since their model is too high in R&D so many avenues dont make sense in their model. The new sickle cell med Casgevy is a good example, costs $3mil/patient.

AFAR and Hevolution are probably the biggest funders right now in the longevity space alongside tech either directly like @barmstrong is doing with New Limit, Sama with Retro and Bezos with Altos. Thats been a big help.